Itraconazole

Major

Itraconazole Cobimetinib Cotellic Increased cobimetinib exposure Details Itraconazole Cyclosporine Injection Atopica Increased cycloSPORINE exposure and risk of cycloSPORINE toxicity (renal dysfunction, cholestasis, paresthesias) Details Itraconazole Cyclosporine Ophthalmic Cequa Increased cycloSPORINE exposure and risk of cycloSPORINE toxicity (renal dysfunction, cholestasis, paresthesias) Details Itraconazole Dabigatran Pradaxa® Increased dabigatran exposure and an increased risk of bleeding Details Itraconazole Dabigatran Etexilate Increased dabigatran exposure and an increased risk of bleeding Details Itraconazole Darolutamide Nubeqa Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse effects Details Itraconazole Dasatinib Phyrago Increased dasatinib exposure and an increased risk of QT interval prolongation Details Itraconazole Deflazacort Emflaza Increased exposure to active metabolite of deflazacort Details Itraconazole Degarelix Injection Firmagon Increased risk of QT interval prolongation Details Itraconazole Deutetrabenazine Austedo An increased risk of QT interval prolongation Details Itraconazole Dexamethasone Injection Decadron Reduced CYP3A substrate exposure and increased dexAMETHasone exposure Details Itraconazole Dexamethasone Ophthalmic Dexacidin® (as a combination product containing Dexamethasone, Neomycin, Polymyxin B) Reduced CYP3A substrate exposure and increased dexAMETHasone exposure Details Itraconazole Diazepam Nasal Spray Valtoco Increased diazePAM exposure and an increased risk of diazePAM-related adverse effects Details Itraconazole Diazepam Rectal Diastat Increased diazePAM exposure and an increased risk of diazePAM-related adverse effects Details Itraconazole Digoxin Cardoxin® Increased digoxin exposure and an increased risk of digoxin toxicity (nausea, vomiting, arrhythmias) Details Itraconazole Docetaxel Beizray Increased DOCEtaxel exposure Details Itraconazole Docetaxel Injection Beizray Increased DOCEtaxel exposure Details Itraconazole Dolasetron Anzemet An increased risk of QT interval prolongation and torsade de pointes Details Itraconazole Dolasetron Injection Anzemet An increased risk of QT interval prolongation and torsade de pointes Details Itraconazole Dolutegravir Juluca® (as a combination product containing dolutegravir, rilpivirine) Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects Details Itraconazole Doravirine Pifeltro Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects Details Itraconazole Doxorubicin Adriamycin Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Itraconazole Dronabinol Marinol Increased cannabinoid exposure and an increased risk of cannabinoid-related adverse effects Details Itraconazole Dutasteride Avodart Increased dutasteride exposure and an increased risk of dutasteride-related adverse effects Details Itraconazole Edoxaban Savaysa Increased edoxaban exposure Details Itraconazole Elacestrant Orserdu Increased elacestrant exposure and an increased risk of elacestrant-related adverse effects Details Itraconazole Enasidenib Idhifa Reduced antifungal exposure and reduced efficacy of antifungal agent Details Itraconazole Encorafenib Braftovi Increased encorafenib exposure, an increased risk of encorafenib-related adverse reactions and an increased risk of QT interval pr... Details Itraconazole Entrectinib Rozlytrek Increased entrectinib exposure, increased frequency or severity of adverse reactions including increased risk of cardiac arrhythmi... Details Itraconazole Eravacycline Injection Xerava Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects Details Itraconazole Erdafitinib Balversa Increased erdafitinib exposure Details Itraconazole Eribulin Injection Halaven An increased risk of QT interval prolongation and torsade de pointes Details Itraconazole Erlotinib Tarceva Increased erlotinib exposure and risk of toxicity Details Itraconazole Estradiol Delestrogen Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects Details Itraconazole Estradiol Topical Divigel Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects Details Itraconazole Estradiol Transdermal Patch Alora® Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects Details Itraconazole Everolimus Afinitor Increased everolimus exposure Details Itraconazole Famotidine Calmicid Reduced itraconazole exposure and an increased risk of QT interval prolongation Details Itraconazole Famotidine Injection Calmicid Reduced itraconazole exposure and an increased risk of QT interval prolongation Details Itraconazole Felbamate Felbatol An increased risk of QT interval prolongation and torsade de pointes Details